Baseline neutrophilia, derived neutrophil‐to‐lymphocyte ratio (dNLR), platelet‐to‐lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel

Nivolumab is a novel therapeutic option in NSCLC, associated with a significant survival gain compared with Docetaxel. However, predictive biomarkers are lacking. The presence of systemic inflammation has been correlated with poor outcome in many cancer types. We aimed to evaluate whether there is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Russo, Alessandro, Franchina, Tindara, Ricciardi, Giuseppina R.R., Battaglia, Alessandra, Scimone, Antonino, Berenato, Rosa, Giordano, Antonio, Adamo, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Rapid Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767577/
https://www.ncbi.nlm.nih.gov/pubmed/29672849
http://dx.doi.org/10.1002/jcp.26609

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767577/
https://www.ncbi.nlm.nih.gov/pubmed/29672849
http://dx.doi.org/10.1002/jcp.26609

Ejemplares similares